stoxline Quote Chart Rank Option Currency Glossary
  
Omeros Corporation (OMER)
3.315  -0.035 (-1.04%)    05-28 16:00
Open: 3.36
High: 3.39
Volume: 207,995
  
Pre. Close: 3.35
Low: 3.28
Market Cap: 192(M)
Technical analysis
2024-05-28 3:54:17 PM
Short term     
Mid term     
Targets 6-month :  4.45 1-year :  5.06
Resists First :  3.81 Second :  4.34
Pivot price 3.54
Supports First :  2.97 Second :  2.47
MAs MA(5) :  3.34 MA(20) :  3.54
MA(100) :  3.65 MA(250) :  3.58
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  23.6 D(3) :  25.5
RSI RSI(14): 45.5
52-week High :  7.8 Low :  0.92
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OMER ] has closed above bottom band by 29.4%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.37 - 3.39 3.39 - 3.4
Low: 3.25 - 3.27 3.27 - 3.29
Close: 3.32 - 3.35 3.35 - 3.38
Company Description

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Headline News

Tue, 28 May 2024
Omeros Co. (NASDAQ:OMER) Shares Bought by Coldstream Capital Management Inc. - Defense World

Mon, 27 May 2024
Should You Buy Omeros (OMER) Ahead of Earnings? - Yahoo Movies Canada

Sun, 26 May 2024
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Shine On

Thu, 16 May 2024
Omeros Corporation (NASDAQ:OMER) Q1 2024 Earnings Call Transcript - Insider Monkey

Thu, 16 May 2024
US Stocks Edge Higher; Initial Jobless Claims Fall - Omeros (NASDAQ:OMER) - Benzinga

Wed, 15 May 2024
OMER Stock Earnings: Omeros Misses EPS for Q1 2024 - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 58 (M)
Shares Float 52 (M)
Held by Insiders 4.3 (%)
Held by Institutions 43 (%)
Shares Short 13,570 (K)
Shares Short P.Month 13,290 (K)
Stock Financials
EPS -2.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.41
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -21.3 %
Return on Equity (ttm) -576.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.83
Qtrly Earnings Growth 0 %
Operating Cash Flow 75 (M)
Levered Free Cash Flow 96 (M)
Stock Valuations
PE Ratio -1.19
PEG Ratio -0.1
Price to Book value -8.08
Price to Sales 0
Price to Cash Flow 2.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android